摘要
目的:观察缬沙坦氨氯地平片联合呋塞米片治疗慢性肾脏病(CKD)合并肾性高血压患者的效果。方法:选取2018年1月至2020年7月该院收治的100例CKD合并肾性高血压患者的临床资料进行回顾性分析。根据治疗方法不同分为观察组(n=50)与对照组(n=50)。对照组给予呋塞米片治疗,观察组在对照组基础上给予缬沙坦氨氯地平片治疗,比较两组疗效、肾功能指标[24 h尿蛋白定量、血肌酐(Scr)、血尿素氮(BUN)]水平、血压[收缩压(SBP)、舒张压(DBP)]和不良反应发生率。结果:观察组治疗总有效率为92.00%,明显高于对照组的76.00%,差异有统计学意义(P<0.05);治疗后,两组24 h尿蛋白定量、Scr和BUN水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组DBP、SBP均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:缬沙坦氨氯地平片联合呋塞米片治疗CKD合并肾性高血压患者可提高疗效,降低其24 h尿蛋白定量、Scr、BUN和血压水平,效果优于单纯呋塞米片治疗。
Objective:To observe effects of Valsartan amlodipine tablets combined with Furosemide tablets in treatment of patients with chronic kidney disease(CKD)and renal hypertension.Methods:The clinical data of 100 patients with CKD and renal hypertension admitted to our hospital from January 2018 to July 2020 were selected for the retrospective analysis.According to different treatment methods,they were divided into observation group(n=50)and control group(n=50).The control group was given Furosemide tablets,while the observation group was treated with Valsartan and amlodipine tablets on the basis of that of the control group.The curative effects,the renal function index levels[24-hour urine protein quantification,blood creatinine(Scr),blood urea nitrogen(BUN)],the blood pressure[systolic blood pressure(SBP),diastolic blood pressure(DBP)]and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 92.00%,which was significantly higher than 76.00%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the 24-hour urine protein quantification as well as the Scr and BUN levels in the two groups were lower than those before the treatment,those of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,DBP and SBP in the two groups were lower than before the treatment,those of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Valsartan amlodipine tablets combined with Furosemide tablets in the treatment of the CKD patients with renal hypertension can improve the curative effects and reduce the 24 h urine protein quantitation as well as the Scr,BUN and blood pressure levels.Moreover,it is superior to single Furosemide tablets.
作者
高伟青
GAO Weiqing(Department of Nephrology of Boluo Branch of Huizhou Central People’s Hospital,Huizhou 516100 Guangdong,China)
出处
《中国民康医学》
2022年第14期18-20,共3页
Medical Journal of Chinese People’s Health
关键词
缬沙坦氨氯地平片
慢性肾脏病
肾性高血压
血压
呋塞米
Valsartan amlodipine tablets
Chronic kidney disease
Renal hypertension
Blood pressure
Furosemide
